Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery

    Not Recruiting
  • participants needed
  • sponsor
    Tokyo Medical and Dental University
Updated on 21 January 2021
renal function
kidney function tests
anesthetic agents


  • It has been shown that patients who undergo liver resection surgery are at high risk for postoperative acute kidney injury (AKI).
    • Sevoflurane may increase the risk for postoperative AKI because of production of compound-A.
    • Therefore, we have planned to investigate the effects of different anesthetic agents on postoperative renal function.
    • Patients undergoing liver resection surgery are randomized into 2 groups.
    • One of the groups receives sevoflurane and the other group receives desflurane.
    • Blood and urine specimen are sampled both pre- and postoperatively, and several biomarkers are compared between the groups.


  1. Design
    • This is a randomized, observer-blinded, controlled trial. 2. Study objectives and hypothesis
    • The aim of this study is to prove the hypothesis that desflurane is safer than sevoflurane in terms of the association with postoperative acute kidney injury (AKI) after liver resection surgery. 3. Inclusion and exclusion criteria
    • Inclusion criteria: Forty adult patients (20 patients in each group) who are planned to undergo liver resection surgery are included.
    • Exclusion criteria: Patients who undergo less invasive liver resection surgery under thoracoscopy or laparoscopy are excluded. Patients with chronic kidney disease, or allergic to any anesthetic agents used in the study (e.g., desflurane, sevoflurane, propofol, remifentanil, rocuronium) are also excluded. 4. Outcome definition
    • AKI is diagnosed based on RIFLE creatinine criteria within 72 hours postoperatively. Serum creatinine is measured preoperatively, on the day of the surgery, and 1st, 2nd, and 3rd postoperative days. 5. Methods
    • Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the agent administered during anesthesia
    • For the quantitative analysis for subclinical AKI, urine interleukin-6 (IL-6), plasma and urine neutrophil gelatinase-associated lipocalin (NGAL), serum cystatin C, urine liver-type fatty acid-binding protein (L-FABP), urine N-acetyl--D-Glucosaminidase (NAG), and urine albumin concentration are measured preoperatively, on the day of the surgery, and 1st postoperative day.
    • Demographic data, preoperative medication, past medical history, perioperative data related to anesthesia and surgery, and data related to outcome are also sampled.
    • Postoperative clinical course is followed until the patients are discharged.
    • Incidence rate of postoperative AKI and biomarkers are compared between the groups.

Condition Cholangiocarcinoma, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA, Malignant neoplasm of gallbladder
Treatment Sevoflurane, Desflurane
Clinical Study IdentifierNCT02174575
SponsorTokyo Medical and Dental University
Last Modified on21 January 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note